文献速递骨显像与常规 SPECT核素与放射性配体治疗

使用氟化钠PET/CT量化纤维性结构不良的骨骼负荷

Quantifying skeletal burden in fibrous dysplasia using sodium fluoride PET/CT.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2019-12-24

这项前瞻性队列研究(n=20)评估了Na18F-PET/CT在纤维性结构不良(FD)中的定量参数,发现个体化SUV截断值可重复区分健康骨与FD病灶,且TLF与骨形成血清标志物及双膦酸盐使用相关,提示Na18F-PET/CT可作为FD临床评估和治疗疗效监测的辅助工具。

要点

  • 个体化SUV截断值可重复区分健康骨与FD病灶,观察者间一致性极高。
  • TLF与ALP、P1NP及FGF-23相关,而SBS仅与FGF-23相关。
  • 使用双膦酸盐的患者TLF更高,而SBS不受用药影响。

核心结论

  • 个体化Na18F-PET/CT SUV截断值可重复区分健康骨与FD,且归一化良好。
  • 骨形成血清标志物与Na18F-PET/CT FD负荷测量强相关,提示其作为FD患者辅助工具的临床相关性优于SBS。
  • 两种影像学方法与工作相关BPI评分升高相关,提示临床适用性。
  • SBS已知不随用药变化,而基线使用双膦酸盐的患者TLF更高,使Na18F-PET/CT成为定量测量FD治疗疗效的有前景工具。

研究设计与样本

  • 前瞻性队列研究,纳入20例患者。
  • 由两名独立读者评估健康骨和FD的Na18F-PET/CT参数,确定定义骨摄取增高的截断值、优化归一化及观察者间一致性(ICC),并与SBS、血清生物标志物、用药及临床参数关联。

主要发现

  • 生理性骨SUV归一化最佳但患者间变异大(总范围4.1-13.7 g/mL),观察者间一致性极高(ICC=0.964)。
  • 患者特异性SUV截断值定义的FD负荷在SUVpeak(ICC=0.994)和TLF(ICC=0.999)上达到近乎完美一致性。
  • TLF与SBS弱相关(R2=0.384,p=0.047)。
  • TLF与血清碱性磷酸酶(R2=0.571,p=0.004)和1型前胶原N端前肽(R2=0.621,p=0.002)正相关,SBS则无(p>0.06)。
  • SBS和TLF均与FGF-23升高相关(分别为R2=0.596,p=0.007和R2=0.541,p=0.015)。

关键数值与推荐

  • TLF在使用双膦酸盐者中更高(p=0.023),SBS则无差异。
  • 平均BPI评分与FGF-23升高相关(R2=0.535,p=0.045)。
  • 工作相关BPI评分与较高SBS(R2=0.518,p=0.024)、较高TLF(R2=0.478,p=0.036)及较高FGF-23水平(R2=0.567,p=0.034)相关。

临床怎么用

  • Na18F-PET/CT个体化SUV截断值可重复区分健康骨与FD病灶。
  • TLF与骨形成标志物强相关,可作为FD负荷评估的辅助工具。
  • TLF可能用于定量监测双膦酸盐治疗疗效,而SBS不随用药变化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To quantify Na18F-PET/CT uptake in relation to clinical and biochemical parameters of fibrous dysplasia (FD) severity and healthy bone (HB) metabolism. Secondary aims: comparing normalization for volume of distribution and determining reproducibility of Na18F-PET/CT uptake parameters in HB and FD. Relating Na18F uptake to skeletal burden score (SBS), bisphosphonate therapy and pain measured by Brief Pain Inventory (BPI). METHODS: In a prospective cohort study (n = 20), Na18F-PET/CT parameters of HB and FD were assessed by two independent readers to determine the cutoff defining increased bone uptake, optimized normalization, and interobserver agreement (ICC) and were related to SBS, serum biomarkers, medication, and clinical parameters. RESULTS: Physiological bone standardized uptake value (SUV) was best normalized but displayed large interpatient variation (total range 4.1-13.7 g/mL), with very high interobserver agreement (ICC = 0.964). FD burden defined by patient-specific SUV cutoffs reached near-perfect agreement for SUVpeak (ICC = 0.994) and total lesion fluorination (TLF) (ICC = 0.999). TLF correlated weakly with SBS (R2 = 0.384, p = 0.047). TLF correlated positively with serum alkaline phosphatase (R2 = 0.571, p = 0.004) and procollagen type 1 N-terminal propeptide (R2 = 0.621, p = 0.002), SBS did not (p > 0.06). SBS and TLF both correlated with increased fibroblast growth factor-23 (R2 = 0.596, p = 0.007 and R2 = 0.541, p = 0.015, respectively). TLF was higher in use of bisphosphonates (p = 0.023), SBS was not. Average BPI scores correlated to increased FGF-23 (R2 = 0.535, p = 0.045), work-related BPI scores to higher SBS (R2 = 0.518, p = 0.024), higher TLF (R2 = 0.478, p = 0.036), and higher levels of FGF-23 (R2 = 0.567, p = 0.034). CONCLUSIONS: Individualized Na18F-PET/CT SUV cutoffs reproducibly discriminated HB from FD and were well-normalized. The strong relations of bone formation serum markers with Na18F-PET/CT FD burden measurements suggest clinical relevance over SBS as an adjunct instrument in FD patients. The correlation of both imaging modalities with increased work-related BPI scores also indicates clinical applicability. Moreover, SBS is known to remain stationary irrespective of use of medication, whereas TLF on Na18F-PET/CT was higher in baseline patients using bisphosphonates. This makes Na18F-PET/CT a promising tool to quantitatively measure treatment efficacy in FD.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. van der Bruggen W, Hagelstein-Rotman M, de Geus-Oei LF, et al. Quantifying skeletal burden in fibrous dysplasia using sodium fluoride PET/CT. Eur J Nucl Med Mol Imaging. 2019. PMID: 31875244. doi:10.1007/s00259-019-04657-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。